F2G

Newark, New Castle, USA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, “Chronic Pulmonary Aspergillosis Drugs Market by Drug Class (Azole Antifungals, Antibiotics, and Others), by Route of…

Application submitted under priority review with PDUFA target action date set for June 17, 2023NDA submission is based on positive data from ongoing Phase 2b open-label study of oral olorofim in 100 patients with invasive fungal infections…

Data are based on analysis of the first 100 patients from an ongoing Phase 2b study of patients who have limited or no treatment options for invasive fungal infectionsOverall, a 44% response rate, defined as complete or partial response,…